Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349290 | 0.96 | AKR1C1 (0.70) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL19335085 | 0.94 | AKR1C1 (0.68) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL19249604 | 0.94 | AKR1C1 (0.68) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL1061631 | 0.94 | AKR1C1 (0.68) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL19335064 | 0.94 | AKR1C1 (0.68) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL844697 | 0.91 | AKR1C1 (0.57) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL4810481 | 0.83 | AKR1C1 (0.55) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL1667343 | 0.83 | AKR1C1 (0.91) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL3113268 | 0.83 | AKR1C1 (0.69) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL3443425 | 0.82 | HDAC4 (0.61) | AKR1C1HDAC4KMT2AHSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-118027395-B | Coating material, preparation method and application thereof, and lithium battery diaphragm | 安徽壹石通材料科学研究院有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-118027395-A | Coating material, preparation method and application thereof, and lithium battery diaphragm | 安徽壹石通材料科学研究院有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-113061098-B | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| CN-113061098-A | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2021-07-02 | — | — | CN | disclosed |
| CN-107021951-B | sGC stimulators | 赛克里翁治疗有限公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| CN-1226886-A | Arylcycloalkane carboxylic acid esters, their use, pharmaceutical compositions and process for their preparation | PHARMACIA & UPJOHN AB (SE) | 1999-08-25 | — | — | CN | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
| EP-0618900-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| US-5519034-A | ANALGESICS | THE BOOTS COMPANY PLC (GB) | 1996-05-21 | — | — | US | disclosed |
| CN-1096780-A | Therapeutic agents containing novel tetrahydroisoquinoline compounds | BOOTS CO PLC (GB) | 1994-12-28 | — | — | CN | disclosed |
| EP-0618900-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013073-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
| US-4117119-A | 15-CYCLOBUTYL-PROSTAGLANDINS | ONO PHARMACEUTICAL COMPANY (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4045468-A | GASTRIC ULCERS | ONO PHARMACEUTICAL COMPANY (JA) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345130-A1 | SGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | AKR1C1 1494/4885HDAC4 3246/4885MEN1 3461/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | AKR1C1 1494/4885HDAC4 3246/4885MEN1 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.